News Quantified

HALO – halozyme therapeutics, inc. (US:NASDAQ)

Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda [Seeking Alpha]

12/4

01:42 pm

halo

Low

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany [Yahoo! Finance]

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}